BEARINGPOINT
24.5.2023 08:55:27 CEST | Business Wire | Press release
Banks today need to continuously upgrade their digital products and services to meet customers’ evolving needs, especially regarding digital payments, and stand out in the fiercely competitive financial services sector.
In a recent client story, BearingPoint explains how it supported Hanseatic Bank in assessing its current IT architecture and then defining the requirements for an integration platform aligned with the bank’s business and IT strategies.
Reshaping the IT infrastructure into a flexible and scalable platform
With Hanseatic Bank, BearingPoint identified various use cases for a minimum viable product (MVP), starting from system integration pain points. A series of workshops held with key stakeholders resulted in developing, implementing, and operating an event-driven integration solution for a payment use case in the cloud that can transform, orchestrate, and process data.
Building on an AWS infrastructure, BearingPoint combined Apache Kafka, an open-source distributed event-streaming platform, and Camunda, a process orchestration platform that designs, orchestrates and improves business processes. The new integration platform including necessary governance is now available to several teams for developing and taking further use cases to production one by one as they arise. Consequently, the future operating model has been redesigned and now focuses on a more decentralized and micro-service approach to bring products and services to market faster, in an iterative way.
“Payment transactions are undergoing major changes. This innovative IT move turned thought leadership into reality in this project. A best-practice approach for modern architecture and efficiency in payments,” said Christian Bruck, Partner at BearingPoint.
Enabling agile ways for building digital service offerings faster
Hanseatic Bank is well-positioned for the future with a modern, scalable, and flexible IT architecture. The bank can now react more quickly to the changing market demands and develop new products and services effectively and efficiently.
Hanseatic Bank has already brought to life an improved digital service that helps customers to select and adjust repayment rates for open credit card transactions. By changing the existing process from an semi-automated processes with human interactions into a reusable real-time process leads to a higher customer satisfaction due to direct response via the banking app or online banking instead of a 24h wait. Further services from different teams are already in the pipeline of the new integration platform.
“The combination of different areas of expertise and team collaboration were key to success. From solution design and business processes to governance and development, BearingPoint delivered with us a successful MVP go-live with a hands-on team,” said Nico Koller, IT Project Lead at Hanseatic Bank.
About Hanseatic Bank
Hanseatic Bank has been at home in Hamburg since it was founded in 1969, but from the outset it has operated with customers and partners throughout Germany. Werner Otto had founded the consumer credit institution to enable customers of Otto Versand to finance their purchases. In 2005, the major French bank Société Générale took over 75 percent of the shares, while the Otto Group continues to hold 25 percent. In the meantime, both the customer base and the product range have expanded significantly. The bank’s business areas now also include deposit business, insurance, receivables management and consumer loans. One specialty is its credit cards with innovative services for customers and cooperation partners. Further information: https://www.hanseaticbank.de.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005700/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom